HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Summary Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wajant, H. Search for Related Content PubMed PubMed Citation Articles by Wajant, H.

Targeting the FLICE Inhibitory Protein (FLIP) in Cancer Therapy

Department of Molecular Medicine Medical Polyclinic, University of Wuerzburg Roentgenring 11, 97070 Wuerzburg, Germany

SUMMARY

In some cases, treatment of ovarian cancer cells with tumor necrosis factor- can induce an apoptotic signal leading to the death of these cells; however, many ovarian malignancies are resistant to the effects of TNF-. A new publication describes how these ovarian tumors may evade death receptor-mediated apoptosis. Apparently, the extracellular signals transduced by death receptors (e.g., TNF receptors) are extinguished before the cascade of caspases, which proteolytically cleave other proteins, can be activated. Overexpression of FLIP, a protein that blocks the caspase activity of FLICE, mediates the observed resistance. Thus, FLIP, which normally prevents inappropriate apoptosis, may become a tumor progression factor. Strategies to overcome this FLIP-mediated blockade of programmed cell death in tumors might become useful for positive prognoses.

Cells of multicellular organisms have the inherent capacity to undergo inducible self-destruction by a highly organized process named programmed cell death, or apoptosis. This "suicidal" capability is utilized especially during development or upon injury or disturbance of tissue homeostasis. However, impairment of the apoptotic machinery of the cell or aberrant expression of anti-apoptotic proteins can contribute to the development of neoplasia and help tumor cells to escape from tumor surveillance by the immune system (1). A significant part of the benefit achieved by chemotherapy relies on the induction of apoptosis in tumor cells. Therefore, the development of resistance to apoptosis is of considerable clinical relevance (1). The central event in apoptosis is the proteolytic activation of cysteine aspartyl-specific proteases (caspases) that cleave defined cellular target proteins and thereby induce the characteristic morphological hallmarks of apoptosis. These effector caspases are triggered by initiator caspases that, in turn, become activated by associating with the signaling complex of death receptors or a cytosolic multiprotein complex called the apoptosome (2, 3).

Death receptors (e.g., Fas) represent a subgroup of the tumor necrosis factor (TNF) receptor (TNFR) superfamily and are structurally defined by an intracellular protein–protein interaction domain, called the death domain (DD), which is critically involved in apoptosis-induction by these receptors (4). Upon stimulation by their corresponding ligands, most death receptors interact with the DD-containing adapter protein FADD (Fas-associated death domain protein) through DD–DD association (Figure 1). Death receptor-bound FADD in turn recruits the proenzyme form of caspase-8 (procaspase-8) thereby initiating the formation of the death-inducing signalling complex (DISC). Procaspase-8 is composed of an N-terminal regulatory prodomain consisting of two death effector domains, which are related to the DD, and a C-terminal caspase homology domain. In the DISC, several procaspase-8 molecules are located in close proximity, leading to their activation by dimerization (5,6). Subsequently, the active caspase-8 dimer is stabilized by a two-step autoproteolytic process (5,6). First, procaspase-8 (p55/53) is cleaved between the p20 and p10 subunits of the caspase homology domain generating a FADD-bound p43/41 intermediate, which is still associated with the p10 subunit (Figure 1). Proteolytic cleavage of the p43/41 intermediate between the prodomain and the p20 subunit results in the release of mature, active caspase-8 (composed of a p20/p10 heteromer) into the cytoplasm. The FADD-bound prodomain can be finally replaced by another procaspase-8 molecule to start a new cycle of caspase-8 activation (4–6). Although caspase-8 activation can occur under nonapoptotic conditions, it typically leads to apoptosis by two different pathways. In "Type I" cells, caspase-8 directly activates effector caspases, especially caspase-3, to an extent sufficient to ensure apoptotic cell death (Figure 2). In contrast, in "Type II" cells caspase-8-induced apoptosis relies on the stimulation of additional mitochondria-dependent amplification mechanisms (4).

View larger version (44K): [in this window] [in a new window]   Figure 1. DISC-mediated activation of caspase-8. Formation of the death-inducing signalling complex (DISC) initially activates unprocessed procaspase-8 by driving its dimerization. Subsequently, dimerized active procaspase-8 is autoproteolytically processed, attaining the mature heterotetrameric state of caspase-8 with DISC-independent activity. The thin arrows indicate proteolytic processing in trans, whereby the asterisks represent the active-site cysteine residues and the arrowheads point to the sites of proteolytic cleavage. However, upon their release by proteolysis—between the DEDs and the p20 subunits—the heterodimers orient themselves into a head-to-tail manner. FADD trimer bound to Fas (not shown). DED, death effector domain; FADD, Fas-associated death domain protein; p20 and p10 represent the subdomains of the caspase homology domain of caspase-8.

View larger version (35K): [in this window] [in a new window]   Figure 2. Apoptotic signaling pathways induced by death receptors and their regulation by FLIP. In type I cells, death receptors (e.g., Fas) induce strong caspase-8 activation, which alone is sufficient to lead to robust processing of effector caspases such as caspase-3 and apoptosis induction (events shown left of the bold dashed line, golden brown region). In type II cells, only low amounts of caspase-8 are activated upon DISC formation. In addition, the action of effector caspases processed by caspase-8 is blocked by IAP proteins. Apoptosis induction in this type of cells is therefore dependent on a mitochondrial amplification loop, which triggers a second pathway leading to caspase-3 activation and furthermore interferes with the action of IAP proteins. IAP, inhibitor of apoptosis protein; BID, BH3-interacting domain death agonist; tBID, truncated BID (a caspase-derived cleavage product of BID); TRAIL, tumor necrosis factor–related apoptosis-inducing ligand; SMAC, second mitochondria-derived activator of caspase; Diablo, direct IAP binding protein with low pI; HtrA2, human serine protease with significant similarity to E. coli HtrA (HtrA2 is also called Omi); Apaf1, apoptotic protease activating factor 1.

Each step in death receptor-mediated apoptosis is well regulated; however, the control of apoptosis imparted by the isoforms of the caspase-8-related FLICE-inhibitory protein (FLIP) is of particular interest. Although more than ten isoforms of FLIP mRNA have been described, only two of them, FLIP_S and FLIP_L, have been significantly studied at the protein level (6). FLIP_L consists of two N-terminal death effector domains and a C-terminal caspase homology domain devoid of enzymatic activity, whereas FLIP_S is only composed of the N-terminal death effector domains and a short C-terminal stretch of amino acids not found in FLIP_L. Both proteins can be recruited to the DISC but they funtion differently: FLIP_S prevents the initial cleavage step of caspase-8 activation between the p20 and the p10 subunit of the caspase homology domain; FLIP_L inhibits the final cleavage between the prodomain and the p20 subunit of the p43/41 intermediate (Figure 2).

There is growing evidence that FLIP can act as a tumor-progression factor (8, 9). For example, FLIP expression correlates with resistance against death receptor-induced apoptosis in a variety of B-cell lymphomas, and FLIP-transfected tumor cell lines develop more aggressive tumors in vivo (8, 9). Conversely, administering chemotherapeutic drugs to sensitize cells that are resistant to death receptor–induced apoptosis often correlates with decreased expression of FLIP (10). Additionally, FLIP is a target of the major anti-apoptotic pathways involved in carcinogenesis, namely the NF- B, Akt/PKB, and MAPK pathways (10). The particular relevance of FLIP for apoptosis-resistance has been pinpointed in recent reports showing that decreased expression of FLIP is sufficient to confer sensitivity against death receptor-induced apoptosis. In the human ovarian epithelial cancer cell line OV2008 transfection with a FLIP-specific antisense construct interferes with TNF-mediated, NF- B–dependent increases in FLIP_S expression and confers sensitivity to the cytotoxic action of TNF, which is mediated by the death receptor TNF-R1 (11). Moreover, FLIP antisense oligonucleotides have been successfully used in three other studies to sensitize resistant prostate cancer cells (12), multiple myeloma cells (13), and chronic lymphocytic leukemia cells (14) to death receptor-induced apoptosis. A further report demonstrates that small interfering RNAs can be used for FLIP downregulation, too (15).

Inhibition of FLIP expression in tumor cells might be of particular importance for TNF-related apoptosis-inducing ligand (TRAIL)-based cancer therapies. TRAIL is the ligand of two death receptors, TRAIL-R1 and TRAIL-R2, and has attracted considerable attention in recent years as a potential anti-cancer reagent because of TRAIL’s ability to induce apoptosis preferentially in tumor cells (10). It is worth noting that TRAIL alone has little, if any, apoptotic effect and therefore requires cotreatment with conventional chemotherapeutic drugs that sensitize tumor cells, but unfortunately also some normal cells, for death receptor-induced apoptosis (10). Chemotherapy has often-pleiotropic effects, including the inhibition of anti-apoptotic pathways that typically regulate a whole battery of effector molecules. For example, the NF- B pathway induces, in a cell-type specific way, almost a dozen anti-apoptotic proteins including FLIP (16, 17). Therefore, it seems conceivable that chemotherapeutic drugs sensitize normal and cancer cells by targeting different cell-type specific effector proteins. Indeed, it has been recently shown that proteasome inhibitors sensitize primary keratinocytes to TRAIL-induced apoptosis by blocking the maturation and activity of caspase-3, most likely by interfering with the function of the inhibitory xIAP protein, an E3 ligase that drives the proteasomal degradation of caspase-3 and Smac/Diablo (18). However, proteasome inhibitors can also sensitize tumor cells for death receptor-induced apoptosis by blocking NF- B–dependent increased expression of FLIP (16, 17). This example illustrates that selective sensitizers of apoptosis might broaden the applicability of anti-cancer strategies related to death-receptor activation. Future studies must now show whether selective decreases in FLIP expression allow for differential sensitization of tumor cells and normal cells for death receptor-induced apoptosis.

Harald Wajant, PhD, is Professor and Head of the Department of Molecular Medicine at the Medical Polyclinic of the University of Wuerzburg. Address correspondence to HW. Email: harald.wajant{at}mail.uni-wuerzburg.de; fax +49 931 201 71070.

References

1. Hanahan, D. and Weinberg, R.A. The hallmarks of cancer. Cell 100, 57–70 (2000).[CrossRef][Medline]
2. Shi, Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell 9, 459–470 (2002).[CrossRef][Medline]
3. Hill, M.M, Adrain, C., and Martin, S.J. Portrait of a killer: The mitochondrial apoptosome emerges from the shadows. Mol. Interv. 3, 19–26 (2003).[Abstract/Free Full Text]
4. Sartorius, U., Schmitz, I., and Krammer, P.H. Molecular mechanisms of death-receptor-mediated apoptosis. Chembiochem 2, 20–29 (2001).[CrossRef][Medline]
5. Donepudi, M., Sweeney, A.M., Briand, C., and Grutter, M.G. Insights into the regulatory mechanism for caspase-8 activation. Mol. Cell 11, 543–549 (2003).[CrossRef][Medline]
6. Boatright, K.M., Renatus, M., Scott, F.L., Sperandio, S., Shin, H., Pedersen, I.M., Ricci, J.E., Edris, W.A., Sutherlin, D.P., Green, D.R., and Salvesen, G.S. A unified model for apical caspase activation. Mol. Cell 11, 529–541 (2003).
   This article and the one above it demonstrate that activation of caspase-8 is initially dependent from dimerization rather than from processing.[CrossRef][Medline]
7. van Loo, G., Saelens, X., van Gurp, M., MacFarlane, M., Martin, S.J., and Vandenabeele, P. The role of mitochondrial factors in apoptosis: A Russian roulette with more than one bullet. Cell Death Differ. 9, 1031–1042 (2001).
8. Thome, M. and Tschopp, J. Regulation of lymphocyte proliferation and death by FLIP. Nat. Rev. Immunol. 1, 50–58 (2001).[CrossRef][Medline]
9. Igney, F.H. and Krammer, P.H. Death and anti-death: Tumour resistance to apoptosis. Nat. Rev. Cancer 2, 277–288 (2002)[CrossRef][Medline]
10. Wajant, H., Pfizenmaier, K., and Scheurich, P. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 7, 449–459 (2002).[CrossRef][Medline]
11. Xiao, C.W., Yan, X., Li, Y., Reddy, S.A. and Tsang, B.K. Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor B-mediated induction of Fas-associated death domain-like interleukin-1ß -converting enzyme-like inhibitory protein. Endocrinology 144, 623–630 (2003).[Abstract/Free Full Text]
12. Hyer, M.L., Sudarshan, S., Kim, Y., Reed, J.C., Dang, J.Y., Schwartz, D.A., and Norris, J.S. Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis. Cancer Biol. Ther. 1, 401–406 (2002).[Medline]
13. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Anderson, K.C., and Treon, S.P. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 99, 2162–2171 (2002).[Abstract/Free Full Text]
14. Pedersen, I.M., Kitada, S., Schimmer, A. et al. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood 100, 2965–2972 (2002).[Abstract/Free Full Text]
15. Siegmund, D., Hadwiger, P., Pfizenmaier, K., Vornlocher, H.P., and Wajant, H. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced spoptosis. Mol. Med. 8, 725–732 (2002).[Medline]
16. Kreuz, S., Siegmund, D., Scheurich, P., and Wajant, H. NF- B inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell. Biol. 21, 3964–3973 (2001).[Abstract/Free Full Text]
17. Micheau, O., Lens, S., Gaide, O., Alevizopoulos, K., and Tschopp, J. NF-kappaB signals induce the expression of c-FLIP. Mol. Cell. Biol. 21, 5299–5305 (2001).
    This publication and the one above it identified FLIP as a target of the NF–B pathway.[Abstract/Free Full Text]
18. Leverkus, M., Sprick, M.R., Wachter, T. et al. Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol. Cell. Biol. 23, 777–790 (2003).
    The first publication to demonstrate that chemotherapeutic drugs could sensitize primary cells for TRAIL-induced apoptosis.[Abstract/Free Full Text]

This article has been cited by other articles:

				E. Schmidt, J. Gutberlet, D. Siegmund, D. Berg, H. Wajant, and J. Waschke Apoptosis is not required for acantholysis in pemphigus vulgaris Am J Physiol Cell Physiol, January 1, 2009; 296(1): C162 - C172. [Abstract] [Full Text] [PDF]

				Y. Lin, X. Liu, P. Yue, D. M. Benbrook, K. D. Berlin, F. R. Khuri, and S.-Y. Sun Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells Mol. Cancer Ther., November 1, 2008; 7(11): 3556 - 3565. [Abstract] [Full Text] [PDF]

				S. M. Raja, S. Chen, P. Yue, T. M. Acker, B. Lefkove, J. L. Arbiser, F. R. Khuri, and S.-Y. Sun The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis Mol. Cancer Ther., July 1, 2008; 7(7): 2212 - 2223. [Abstract] [Full Text] [PDF]

				Y. Ding, K. J. Choi, J. H. Kim, X. Han, Y. Piao, J.-H. Jeong, W. Choe, I. Kang, J. Ha, H. J. Forman, et al. Endogenous Hydrogen Peroxide Regulates Glutathione Redox via Nuclear Factor Erythroid 2-Related Factor 2 Downstream of Phosphatidylinositol 3-Kinase during Muscle Differentiation Am. J. Pathol., June 1, 2008; 172(6): 1529 - 1541. [Abstract] [Full Text] [PDF]

				H. A. Elrod, Y.-D. Lin, P. Yue, X. Wang, S. Lonial, F. R. Khuri, and S.-Y. Sun The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway Mol. Cancer Ther., July 1, 2007; 6(7): 2029 - 2038. [Abstract] [Full Text] [PDF]

				Y. Qiu, X. Liu, W. Zou, P. Yue, S. Lonial, F. R. Khuri, and S.-Y. Sun The Farnesyltransferase Inhibitor R115777 Up-regulates the Expression of Death Receptor 5 and Enhances TRAIL-Induced Apoptosis in Human Lung Cancer Cells Cancer Res., May 15, 2007; 67(10): 4973 - 4980. [Abstract] [Full Text] [PDF]

				X. Liu, P. Yue, S. Chen, L. Hu, S. Lonial, F. R. Khuri, and S.-Y. Sun The Proteasome Inhibitor PS-341 (Bortezomib) Up-Regulates DR5 Expression Leading to Induction of Apoptosis and Enhancement of TRAIL-Induced Apoptosis Despite Up-Regulation of c-FLIP and Survivin Expression in Human NSCLC Cells Cancer Res., May 15, 2007; 67(10): 4981 - 4988. [Abstract] [Full Text] [PDF]

				X. Liu, P. Yue, A. H. Schonthal, F. R. Khuri, and S.-Y. Sun Cellular FLICE-Inhibitory Protein Down-regulation Contributes to Celecoxib-Induced Apoptosis in Human Lung Cancer Cells Cancer Res., December 1, 2006; 66(23): 11115 - 11119. [Abstract] [Full Text] [PDF]

				Y. Chen, J. Xu, N. Jhala, P. Pawar, Z. B. Zhu, L. Ma, C.-H. Byon, and J. M. McDonald Fas-Mediated Apoptosis in Cholangiocarcinoma Cells Is Enhanced by 3,3'-Diindolylmethane through Inhibition of AKT Signaling and FLICE-Like Inhibitory Protein Am. J. Pathol., November 1, 2006; 169(5): 1833 - 1842. [Abstract] [Full Text] [PDF]

				X. Cai, C. Stoicov, H. Li, J. Carlson, M. Whary, J. G. Fox, and J. Houghton Overcoming Fas-Mediated Apoptosis Accelerates Helicobacter-Induced Gastric Cancer in Mice Cancer Res., December 1, 2005; 65(23): 10912 - 10920. [Abstract] [Full Text] [PDF]

				F. Jin, X. Liu, Z. Zhou, P. Yue, R. Lotan, F. R. Khuri, L. W.K. Chung, and S.-Y. Sun Activation of Nuclear Factor-{kappa}B Contributes to Induction of Death Receptors and Apoptosis by the Synthetic Retinoid CD437 in DU145 Human Prostate Cancer Cells Cancer Res., July 15, 2005; 65(14): 6354 - 6363. [Abstract] [Full Text] [PDF]

This Article Summary Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wajant, H. Search for Related Content PubMed PubMed Citation Articles by Wajant, H.